| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697547 | Cancer Treatment Reviews | 2017 | 23 Pages |
Abstract
One year of trastuzumab prolongs overall, and disease-free survivals in women with early-stage HER2 positive breast cancer compared to shorter durations and this should remain as the standard of care. Cardiotoxicity increased significantly with the 1-year treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Bishal Gyawali, Saroj Niraula,